Dr. Wolff Schmiegel

Dr. Wolff Schmiegel is a German specialist in internal medicine, gastroenterology, and medical oncology. He studied medicine at the Catholic University of Leuven in Belgium, at the Ruhr University in Bochum, Germany, and at the University of Bonn, Germany. After his appointment as a senior physician at the first medical university clinic and polyclinic at the University Clinic Hamburg-Eppendorf, Dr. Schmiegel was appointed to a C3 professorship in 1993 (Gastroenterology/hepatology/gastroenterological oncology) by the University of Hamburg and subsequently an appointment as a university professor and director of the University Hospital Knappschaftskrankenhaus Bochum and also the head of the Department of Gastroenterology/Hepatology at the University Hospital Bergmannsheil Bochum.

From 1978 to 1981, Dr. Schmiegel worked in the Department of Clinical Immunology at the University Hospital Eppendorf on a tumor immunological scientific focus with the generation of tumor-specific monoclonal antibodies against pancreatic carcinoma and colon carcinoma cell structures. An anti-EGF receptor-specific monoclonal antibody was initially used preclinically and then clinically for the first time in pancreatic carcinoma patients. In 1999, Dr. Schmiegel coordinated the first oncological S3 evidence-based guideline on colorectal cancer, which was the basis for the introduction of colorectal cancer screening and early detection colonoscopy (2002) by the GBA. This was followed by the continuation of clinical therapy studies for gastrointestinal tumors and work to improve the early detection of colon cancer and the identification of risk patients as a center for familial colon cancer of the German Cancer Aid. Prognostic and predictive biomarkers for gastroenterological tumor diseases could be identified, and their clinical use also tested with the so-called liquid biopsy.

Dr. Schmiegel has published around 700 medical articles and is co-editor of two standard works on internal medicine and gastroenterology. He was the president of the German Association of Digestive and Metabolic Diseases and the German Cancer Society. Dr. Schmiegel is currently on the Board of Trustees of the Foundation German Cancer Aid.